If your oncologist has just mentioned immunotherapy as a possible option, you have probably already spent an evening searching for answers. Does having lung cancer or melanoma automatically mean you qualify? Why did a relative with what seems like a similar diagnosis get a completely different treatment plan? Is there a test that simply says yes or no?
These are fair questions, and the honest answer is that immunotherapy eligibility is rarely a single yes or no decision. Immunotherapy for cancer is closer to a puzzle that an oncologist puts together using your cancer type, your test reports, your treatment history, and your general health, all at the same time. This article looks at who can get immunotherapy, who is eligible for immunotherapy, and how that decision actually gets made, so that when you sit down with your oncologist, you understand what they are looking at and why.
Two Different Questions That Often Get Mixed Up
There is a difference between “can immunotherapy treatment be used for this type of cancer” and “is immunotherapy the right choice for this particular patient.” Most of the confusion around immunotherapy for cancer patients comes from treating these as the same question, and it is also what makes an immunotherapy treatment decision feel confusing from the outside.
The first question has a medical, evidence-based answer. Researchers and regulatory bodies have studied immunotherapy cancer treatment in specific cancers, at specific stages, often in combination with specific biomarker results, and approved it for use in those settings. This is why immunotherapy is a standard option for some cancers and not currently a standard option for others.
The second question is personal. Even when immunotherapy is an approved option for a cancer type, your oncologist still has to weigh your biomarker results, your organ function, your previous treatments, and your overall health before deciding it is the right next step for you specifically. Two patients with the same diagnosis and the same stage can walk out of the same clinic with two different treatment plans, and both plans can be correct for the person they were made for.
How Doctors Decide on Immunotherapy
There is no single form or checklist that determines immunotherapy eligibility criteria. Understanding how doctors decide on immunotherapy means looking at several pieces of information together, not in isolation, which is why the immunotherapy eligibility criteria for cancer can look different from one patient to the next even within the same diagnosis.
Cancer Type and Immunotherapy Drugs for Cancer
Immune checkpoint inhibitors, the most widely used immunotherapy drugs for cancer, have established roles in certain cancers and specific clinical situations. This does not mean every cancer responds to immunotherapy in the same way, or that immunotherapy is available as an option regardless of diagnosis. Some cancers have strong, well-studied evidence supporting immunotherapy. Others have more limited evidence, and immunotherapy may only be considered in select circumstances, as part of a clinical protocol, or not at all. Your oncologist will know where your specific cancer type and subtype falls on that spectrum.
Cancer Stage and Treatment Setting
Stage changes what immunotherapy is being asked to do, and it is one of the biggest factors in when is immunotherapy recommended. In early, localised cancers, it may sometimes be used before surgery to shrink a tumour, or after surgery to lower the chance of the cancer returning. In advanced, recurrent, or metastatic disease, immunotherapy for advanced cancer is often used to control the disease for as long as possible, sometimes as the first treatment tried and sometimes after other treatments have been used. The point is that stage does not just affect whether immunotherapy is used, it affects how, when, and alongside what other treatment.
Immunotherapy Biomarkers: Reading the Tumour’s Own Signals
A biomarker is simply a measurable feature of your tumour or blood that gives doctors information about how the cancer is likely to behave or respond to treatment. Immunotherapy biomarkers help answer a practical question: is this particular tumour the kind that the immune system, once unlocked, is likely to recognise and attack?
Some of the biomarkers your oncologist may look at include PD-L1 expression, microsatellite instability (MSI) status, mismatch repair (MMR) status, and in certain cancers, tumour mutation burden or other molecular markers. None of these numbers work as a stand-alone pass or fail result. They are read alongside the cancer type, the stage, and the specific drug being considered.
PD-L1 Testing for Immunotherapy Explained
PD-L1 is a protein that some cancer cells use to switch off nearby immune cells, essentially telling them to leave the tumour alone. Understanding how immunotherapy works starts here: PD-L1 testing for immunotherapy measures how much of this protein is present on the tumour sample, usually taken from a biopsy.
In some cancers, particularly certain types of lung cancer, a higher PD-L1 level can influence whether immunotherapy is used on its own or combined with chemotherapy. In other cancers, PD-L1 testing may not be required at all, or may be interpreted differently, because the biology of that cancer does not depend on the same signal. A high PD-L1 result does not guarantee that treatment will work, and a low result does not automatically rule immunotherapy out. This is exactly why the test result is one input into the decision rather than the decision itself.
Previous Treatment and How the Cancer Responded
Your treatment history matters more than many patients expect. Your oncologist will typically review what chemotherapy, targeted therapy, radiation, or surgery you have already had, how the cancer responded, whether it progressed on a particular drug, and whether you have received immunotherapy before. This history helps determine whether immunotherapy makes sense as the next step, whether it should be combined with something else, or whether a different approach is more appropriate at this point in your care.
Overall Health, Organ Function, and Existing Conditions
Because immunotherapy works by adjusting the immune system rather than attacking the tumour directly, your general health plays a real role in the decision. Oncologists typically assess organ function through blood tests, review any existing autoimmune conditions, take note of other medications you are on, and consider how you tolerated previous cancer treatments. Patients with certain autoimmune diseases, for example, may need a more careful conversation, since immunotherapy increases immune activity and could potentially aggravate those conditions. This is not a simple list of automatic disqualifications. It is a clinical judgement made by weighing potential benefit against potential risk for that individual.
Immunotherapy for Different Cancers
Depending on current medical evidence, immunotherapy for different cancers looks different from one diagnosis to the next, and immunotherapy treatment for different cancer types is not interchangeable. Immunotherapy has a recognised place in the treatment of several cancer types, including:
- Non-small cell lung cancer, particularly in certain PD-L1 expression ranges
- Melanoma, including advanced and some earlier-stage cases
- Kidney cancer, often in combination regimens
- Bladder and other urothelial cancers
- Certain head and neck cancers
- Selected gastrointestinal cancers, including some with MSI-high or dMMR results
- Certain gynaecological cancers
- Some blood cancers, such as classical Hodgkin lymphoma
This list describes where immunotherapy is an option worth discussing, not a guarantee. Within each of these cancer types, only some patients will meet the biomarker, stage, and health criteria that make immunotherapy appropriate for them. A diagnosis on this list is a reason to have the conversation with your oncologist, not a reason to assume the outcome of that conversation.
Tests Needed Before Immunotherapy
The exact tests needed before immunotherapy depend on your cancer type and the specific drug being considered, so there is no single universal checklist. That said, the evaluation before immunotherapy commonly includes some combination of the following:
- A detailed pathology review of the tumour tissue
- Biomarker testing, which may include PD-L1, MSI, or MMR depending on the cancer
- Molecular or genomic testing where it is relevant to the diagnosis
- Blood tests to check liver, kidney, and thyroid function, along with blood counts
- Imaging, such as a CT or PET scan, to understand the current extent of disease
- A review of previous treatments and how the cancer responded to them
Some of this testing, particularly biomarker analysis on tumour tissue, can take a week or two depending on how the sample needs to be processed. This waiting period is often frustrating for patients who want to start treatment immediately, but it is what allows the oncologist to recommend a plan based on your tumour’s actual characteristics rather than a general assumption.
“Is Immunotherapy Suitable for Me?”
“Is immunotherapy suitable for me?” is the question almost every patient eventually asks, and it is not one that can be answered from a blog post, a forum thread, or someone else’s treatment experience. What we can tell you is what to bring into that conversation with your oncologist:
- Your exact cancer type and subtype
- Your stage and current extent of disease
- Your pathology report
- Your biomarker results, if testing has already been done
- Details of any previous cancer treatment and how you responded to it
- Your current overall health, including any other medical conditions and medications
- Any questions you have about potential benefits, risks, and alternative treatment options
Bringing this information to your consultation, rather than trying to work out eligibility on your own beforehand, is what allows your oncologist to give you a genuinely individual answer instead of a general one.
Immunotherapy Alone or Combined With Other Treatments
Immunotherapy does not necessarily replace chemotherapy, targeted therapy, surgery, or radiation. Looking at the full range of immunotherapy treatment options, depending on the cancer type, stage, and biomarker results, it may be used on its own, combined with chemotherapy, combined with a targeted treatment, given before other treatments to shrink a tumour, or given after other treatments as part of a longer-term plan.
At Oorja, this is part of why treatment planning often draws on more than one discipline. Immunotherapy decisions are frequently made alongside the same considerations used in precision therapy, where genomic and biomarker testing guides the choice between immune-based treatment, targeted therapy, or a combination of both. There is no fixed hierarchy where one treatment is always considered stronger than another. The right combination depends entirely on what is happening in your specific case.
What Immunotherapy Can and Cannot Offer
Immunotherapy has changed outcomes for many patients with cancers that historically had limited treatment options, and for some people, the response can be significant and long-lasting. It is also true that immunotherapy does not work for everyone, even within cancer types where it is an established option. Response depends heavily on the biomarker profile of the individual tumour.
Immunotherapy also carries its own risks. Because it activates the immune system, it can occasionally cause the immune system to attack healthy tissue, leading to inflammation in organs such as the lungs, liver, thyroid, or gut. These immune-related side effects usually need to be monitored closely and sometimes require adjusting or pausing treatment. Regular follow-up, blood tests, and scans are part of the process, not an optional extra.
None of this makes immunotherapy a lesser option. It simply means it is a treatment that requires careful selection and ongoing monitoring, like any other serious medical intervention.
Personalised Evaluation at Oorja Oncology Centre, Chembur
At Oorja Oncology Centre in Chembur, Mumbai, treatment decisions are built around the individual patient rather than the diagnosis alone. Dr. Suhas Agre, Medical Oncologist, and Dr. Madhura Ambekar Agre, Hemato-Oncologist, review each patient’s pathology reports, biomarker results, and treatment history before recommending a path forward, whether that involves immunotherapy, targeted therapy, precision therapy, or a combination delivered through our outpatient chemotherapy daycare setup, along with supportive services to help manage the treatment journey alongside it.
If you or a family member has been told that immunotherapy could be an option, the most useful next step is a consultation where your specific reports and history can be reviewed in full. That conversation, not an online checklist, is what determines whether immunotherapy is the right fit for your situation. You can reach Oorja Oncology Centre in Chembur to discuss your diagnosis, test results, and treatment options with our oncology team.
Frequently Asked Questions
Who can get immunotherapy?
There is no single profile of who qualifies. Eligibility depends on the specific cancer type and stage, biomarker results such as PD-L1 or MSI/MMR status where relevant, previous treatments and how the cancer responded, and the patient’s overall health and organ function. An oncologist reviews all of these together rather than deciding based on diagnosis alone.
How do doctors decide if immunotherapy is suitable?
Doctors look at the cancer type and whether immunotherapy has an established role in it, the stage and treatment setting, biomarker test results, the patient’s treatment history, and their general health, including organ function and any existing autoimmune or other conditions. These factors are weighed together, not used as a simple checklist.
What tests are needed before immunotherapy?
This varies by cancer type, but commonly includes pathology review, biomarker testing such as PD-L1 or MSI/MMR where relevant, blood tests to check organ function, and imaging to assess the current extent of disease. The exact combination depends on the cancer being treated and the specific drug being considered.
Is immunotherapy suitable for every cancer patient?
No. Immunotherapy has an established role in certain cancer types and clinical situations, but not every patient within those cancer types will be a suitable candidate. Some cancers do not currently have strong evidence supporting immunotherapy as a standard treatment at all.
Does PD-L1 testing determine whether I can get immunotherapy?
PD-L1 testing is one factor among several, and it is not required or interpreted the same way for every cancer. A high PD-L1 result can support the use of immunotherapy in some cancers, but it does not guarantee a response, and a lower result does not automatically exclude immunotherapy as an option.
Can immunotherapy be used for advanced cancer?
Yes, immunotherapy is used in advanced and metastatic cancer for several cancer types, often as part of first-line or later-line treatment depending on biomarker results and previous treatment. It is also used in some earlier-stage and localised cancers, so stage alone does not decide the answer.
Can immunotherapy be given with chemotherapy?
In several cancers, immunotherapy is combined with chemotherapy rather than used alone, particularly when biomarker results suggest that combination is likely to be more effective than either treatment individually. Whether combination therapy is appropriate depends on the specific cancer, stage, and biomarker profile.
How do doctors choose between immunotherapy and other cancer treatments?
There is no fixed order in which treatments are tried. Oncologists consider the cancer type, stage, biomarker and genomic test results, prior treatment response, and the patient’s overall health to decide whether immunotherapy, targeted therapy, chemotherapy, or a combination is the most appropriate approach for that individual.